Jun 17, 2025 11:28AM
Mar 15, 2025 04:00PM
Jun 14, 2024 07:30AM
Jun 14, 2024 07:30AM
Nov 2, 2023 07:03AM
Nov 2, 2023 07:00AM
May 4, 2023 07:30AM Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
Feb 23, 2023 07:30AM
Jan 11, 2023 07:30AM
Jan 11, 2023 07:30AM
Nov 12, 2022 04:30PM
Nov 5, 2022 04:00PM
Nov 3, 2022 07:30AM
Sep 16, 2022 07:16AM Regeneron (REGN) and Intellia (NTLA) Report Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001
Sep 16, 2022 07:15AM
Sep 16, 2022 07:15AM
Sep 16, 2022 07:02AM
Sep 16, 2022 07:00AM
Sep 14, 2022 01:00AM
Sep 1, 2022 04:01PM
Sep 1, 2022 04:01PM Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema
Aug 23, 2022 09:59AM
Aug 4, 2022 07:30AM
May 25, 2022 03:00PM
May 5, 2022 07:30AM
Mar 1, 2022 07:30AM
Feb 24, 2022 07:30AM
Feb 3, 2022 03:31PM Intellia Therapeutics (NTLA) PT Lowered to $108 at Wedbush, Following Strategic Business Update
Feb 3, 2022 09:15AM
Feb 3, 2022 08:43AM
Feb 3, 2022 07:30AM
Feb 3, 2022 07:30AM
Oct 20, 2021 07:31AM
Oct 20, 2021 07:30AM
Sep 16, 2021 07:31AM Intellia Therapeutics (NTLA) Announces U.S. FDA Acceptance of IND for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia
Sep 16, 2021 07:30AM
Jun 29, 2021 09:27AM
Jun 22, 2021 07:01AM
Jun 22, 2021 07:00AM
Dec 1, 2020 09:25AM
Nov 30, 2020 05:41PM
Oct 5, 2020 07:33AM Intellia Therapeutics (NTLA) Announces John F. Crowley to Board
Oct 5, 2020 07:30AM
Jun 2, 2020 09:28AM
Jun 1, 2020 05:30PM
May 15, 2018 09:20AM
Mar 8, 2018 09:30AM
Aug 29, 2017 09:33AM
Aug 28, 2017 12:25PM Intellia Therapeutics (NTLA) Gains on Volume Amid Gilead/Kite Deal
Jul 25, 2017 05:46AM

1,155,209 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All